Buckley Wealth Management LLC Lowers Stock Position in Amgen Inc. (NASDAQ:AMGN)

Buckley Wealth Management LLC lessened its holdings in Amgen Inc. (NASDAQ:AMGN) by 1.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 26,490 shares of the medical research company’s stock after selling 275 shares during the period. Amgen comprises 2.7% of Buckley Wealth Management LLC’s holdings, making the stock its 12th biggest position. Buckley Wealth Management LLC’s holdings in Amgen were worth $7,630,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the business. OFI Invest Asset Management bought a new position in shares of Amgen during the 3rd quarter worth approximately $26,000. Briaud Financial Planning Inc acquired a new position in Amgen during the 3rd quarter valued at approximately $26,000. VisionPoint Advisory Group LLC acquired a new position in Amgen during the 2nd quarter valued at approximately $28,000. Strategic Investment Solutions Inc. IL acquired a new position in Amgen during the 1st quarter valued at approximately $28,000. Finally, Providence Capital Advisors LLC acquired a new position in Amgen during the 3rd quarter valued at approximately $30,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Morgan Stanley cut their price objective on shares of Amgen from $281.00 to $278.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 7th. SVB Leerink downgraded shares of Amgen from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $324.00 to $318.00 in a report on Wednesday, February 7th. Daiwa Capital Markets upgraded shares of Amgen from a “neutral” rating to a “buy” rating and increased their target price for the company from $264.00 to $320.00 in a research report on Thursday, December 21st. Leerink Partnrs cut shares of Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 7th. Finally, The Goldman Sachs Group raised their price objective on shares of Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a research report on Wednesday, February 7th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $295.30.

Amgen Trading Up 1.6 %

Shares of NASDAQ AMGN traded up $4.53 on Wednesday, reaching $286.30. 2,255,872 shares of the company traded hands, compared to its average volume of 3,053,429. Amgen Inc. has a fifty-two week low of $211.71 and a fifty-two week high of $329.72. The company has a 50 day moving average of $290.44 and a 200 day moving average of $280.66. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 10.14. The stock has a market capitalization of $153.43 billion, a PE ratio of 22.94, a P/E/G ratio of 2.63 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. The firm had revenue of $8.20 billion during the quarter, compared to the consensus estimate of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The company’s revenue was up 19.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $4.09 EPS. On average, equities research analysts forecast that Amgen Inc. will post 19.48 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be paid a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 3.14%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is currently 72.06%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.